Drug intelligence / Profile preview

infliximab + risankizumab

Development stage: Preclinical
Lead developer: AbbVie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of infliximab, a TNF-α inhibitor, and risankizumab, an IL-23 antagonist. Infliximab binds to soluble and transmembrane forms of TNF-α, preventing it from interacting with its receptors and disrupting pro-inflammatory cascade signaling. Risankizumab binds specifically to the p19 subunit of IL-23, inhibiting IL-23 from interacting with the IL-23 receptor and subsequent signaling. This combination targets multiple inflammatory pathways simultaneously and may be considered for refractory inflammatory conditions.

Targets

IL23A (Interleukin-23 p19 Subunit)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on infliximab + risankizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on infliximab + risankizumab.

Explore the full profile